Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months. - Université de Bretagne Occidentale
Conference Poster Year : 2019

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Domains

Immunology

Geneviève Michel  : Connect in order to contact the contributor

https://hal.univ-brest.fr/hal-02151122

Submitted on : Friday, June 7, 2019-4:59:02 PM

Last modification on : Wednesday, January 17, 2024-9:52:07 AM

No file

Dates and versions

hal-02151122 , version 1 (07-06-2019)

Identifiers

  • HAL Id : hal-02151122 , version 1

Cite

Alain Saraux, Thomas Barnetche, Guy Baudens, Isabelle Idier, Flore Delaporte, et al.. Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.. EULAR 2019, Jun 2019, MADRID, Spain. ⟨hal-02151122⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST IMMUNO IBSAM
28 View
0 Download

Share

More